FGP
AVLN

Freestone Grove Partners’s Avalyn Pharma AVLN Stock Holding History

Freestone Grove Partners’s Portfolio AVLN Stock Details AVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65M Buy
+50,000
New +$1.44M 0.01% 449

Other funds holding AVLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Freestone Grove Partners's AVLN Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Avalyn Pharma (AVLN) in Q2 2026: 50,000 shares worth $1.65M. The stake represents 0.01% of the portfolio and ranks #449 among its holdings.

92 funds tracked by Wall St. Rank hold AVLN as of Q2 2026.

  • Freestone Grove Partners held 50,000 shares of Avalyn Pharma worth $1.65M as of Q2 2026.
  • Avalyn Pharma was a new Freestone Grove Partners position in Q2 2026.
  • Avalyn Pharma made up 0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #449 holding.
  • 92 funds tracked by Wall St. Rank held Avalyn Pharma as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.